Suspension of sales of Reductil®, Ectiva® and Reduxade® in Singapore

Abbott Laboratories (S) Pte Ltd is informing healthcare professionals of the suspension of sales of Reductil®, Ectiva® and Reduxade® from the Singapore market at the request of HSA. HSA's decision to suspend sibutramine took into consideration the results of the SCOUT (Sibutramine Cardiovascular Outcomes) study, the use of sibutramine in the local context and the developments in other international jurisdictions. SCOUT study is an approximately 10,000 patient, six-year study requested by European regulatory authorities as a post-marketing commitment to evaluate cardiovascular safety in high-risk patients. Patients treated with sibutramine experienced a 16% increased risk of a primary outcome event of non-fatal myocardial infarction, non-fatal stroke, resuscitated cardiac arrest, or cardiovascular death compared with placebo-treated patients. This result was attributed to an increased risk of non-fatal myocardial infarction and stroke.

Only abstracts of the Dear Healthcare Professional Letters (DHCPL) are provided on this website. Details of these letters can be found in the MOH Alert System, which is accessible via the Health Professionals Portal (HPP), a one-stop portal for all healthcare professionals in Singapore. Dentists, medical doctors and pharmacists may access HPP at https://hpp.moh.gov.sg and follow the procedures below to access the MOH Alert system.

Step 1: Select your profession under ‘For Healthcare Professionals’.

Step 2: Click on ‘Useful links’.

Step 3: Click on ‘MOH Alert’ and log in via Singpass.

Step 4: Click on ‘Drug Alerts’ or ‘Med Device Alerts’ to view the DHCPLs.